Patents by Inventor Hinrich Abken
Hinrich Abken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230142916Abstract: Immune cells containing a nucleic acid construct, also referred to as a vector or viral vector, for use in immune therapy, e.g. for use in the treatment of cancer, or for use in the treatment of autoimmune disease, or for use in the treatment of GvH or HvG. The nucleic acid construct comprises a second expression cassette for constitutive expression of a CAR or a TCR, the binding of which to its target antigen results in signalling and induces the expression of an effector molecule from a first expression cassette, which is contained on the same nucleic acid construct, and which first expression cassette encodes the effector molecule under the control of a promoter inducible by signalling of the CAR or TCR.Type: ApplicationFiled: June 22, 2020Publication date: May 11, 2023Inventors: Axel Schambach, Katharina Zimmermann, Hinrich Abken, Johannes Kühle
-
Patent number: 11512139Abstract: The present invention provides a chimeric antigen receptor (CAR), comprising an extracellular part, at least one intracellular signaling domain, and at least one transmembrane domain, wherein the extracellular part of said CAR comprises a) at least one antigen binding domain, and b) at least one cytokine receptor activating or blocking domain. The invention also provides isolated nucleic acid molecule(s) encoding for the said CAR, a cell comprising said nucleic acid molecule(s), a cell expressing said CAR and therapeutic uses of said CAR.Type: GrantFiled: December 20, 2016Date of Patent: November 29, 2022Assignee: Miltenyi Biotec B.V. & Co. KGInventors: Hinrich Abken, Andreas Hombach
-
Publication number: 20220213204Abstract: The present invention relates to proteins which comprise (i) a CD25-specific binding domain, (ii) a linker domain, connecting domain (i) and domain (iii), (iii) a transmembrane domain, and (iv) a signalling domain. The present invention furthermore relates to nucleic acids encoding the proteins, expression constructs for expressing the protein in a host cell and host cells. The present invention further relates to pharmaceutical compositions comprising said protein(s), nucleic acid(s), expression construct(s) or host cell(s). The proteins of the invention are CD25-specific chimeric antigen receptors that are suitable for generating CD25-specific immune cells, which can be used e.g. in the treatment of inflammation.Type: ApplicationFiled: June 3, 2020Publication date: July 7, 2022Inventors: HINRICH ABKEN, ANDREAS HOMBACH, MANUEL EHLING
-
Publication number: 20220002401Abstract: In a first aspect, the present invention relates to a recombinant polypeptide containing a domain comprising at least two antibody units whereby the first antibody unit is an an anti-CD30 single chain antibody unit while the second antibody unit is a antibody unit being specific for an antigen present on the surface of a pre-determined target cell. In particular, the present invention relates to a recombinant polypeptide containing at least the following domains starting from the N-terminus to the C-terminus: a first domain containing an anti-CD30 single chain anti-body unit, in particular, HRS3 scFv of SEQ ID No. 2 or homologs thereof having at least 70% identity with SEQ ID No. 2 binding specifically to CD30, and an antibody unit said antibody unit being specific for an antigen present on the surface of a predetermined target cell, in particular, being specific for a tumor-associated antigen; optionally a spacer domain; a trans-membrane domain; and a cytoplasmatic signalling domain.Type: ApplicationFiled: November 12, 2020Publication date: January 6, 2022Inventors: Hinrich ABKEN, Andreas HOMBACH
-
Publication number: 20210371491Abstract: The present invention relates to a novel chimeric antigen receptor (CAR) comprising an antigen-binding fragment which binds specifically to PSMA antigen, and a method of manufacturing high-quality CAR T cell products by transfection and/or transduction of T cells therewith, which allows to eradicate tumors in vivo alone or in combination with pharmaceutical drugs, such chemotherapies, biopharmaceutical drugs, such as antibodies, or small-molecule drugs, such as protein kinase inhibitors.Type: ApplicationFiled: June 17, 2019Publication date: December 2, 2021Applicant: Albert-Ludwigs-Universitaet FreiburgInventors: Toni CATHOMEN, Jamal ALZUBI, Viviane DETTMER, Philipp WOLF, Susanne SCHULTZE-SEEMANN, Irina KUCKUCK, Hinrich ABKEN, Johannes KUEHLE
-
Publication number: 20210040226Abstract: The present invention provides a chimeric antigen receptor (CAR), comprising an extracellular part, at least one intracellular signaling domain, and at least one transmembrane domain, wherein the extracellular part of said CAR comprises a) at least one antigen binding domain, and b) at least one cytokine receptor activating or blocking domain. The invention also provides isolated nucleic acid molecule(s) encoding for the said CAR, a cell comprising said nucleic acid molecule(s), a cell expressing said CAR and therapeutic uses of said CAR.Type: ApplicationFiled: December 20, 2016Publication date: February 11, 2021Inventors: Hinrich Abken, Andreas Hombach
-
Publication number: 20200407458Abstract: In a first aspect, the present disclosure relates to genetically modified T-cells having a chimeric antigen receptor for use in adoptive cell therapy for treating CD30+cancer in a subject need thereof. In particular, the present disclosure relates to a T-cell containing a specific chimeric antigen receptor being toxic to CD30+cancer cells while being non-toxic to CD30+non-cancer cells. In a further aspect, the present disclosure relates to a specific chimeric antigen receptor and the nucleic acid molecule encoding the receptor as well as vectors and cells containing the same. Finally, the present disclosure relates to the use of the chimeric antigen receptor for use in improving persistence and amplification of lymphocyte containing the same and the use of specific peptides for improving persistence and amplification of genetically modified lymphocytes expressing the same.Type: ApplicationFiled: September 14, 2020Publication date: December 31, 2020Inventors: Markus CHMIELEWSKI, Andreas HOMBACH, Hinrich ABKEN
-
Patent number: 10865243Abstract: In a first aspect, the present invention relates to a recombinant polypeptide containing a domain comprising at least two antibody units whereby the first antibody unit is an anti-CD30 single chain antibody unit while the second antibody unit is a antibody unit being specific for an antigen present on the surface of a predetermined target cell. In particular, the present invention relates to a recombinant polypeptide containing at least the following domains starting from the N-terminus to the C-terminus: a first domain containing an anti-CD30 single chain antibody unit, in particular, HRS3 scFv of SEQ ID No. 2 or homologs thereof having at least 70% identity with SEQ ID No. 2 binding specifically to CD30, and an antibody unit said antibody unit being specific for an antigen present on the surface of a predetermined target cell, in particular, being specific for a tumor-associated antigen; optionally a spacer domain; a trans-membrane domain; and a cytoplasmatic signalling domain.Type: GrantFiled: July 16, 2015Date of Patent: December 15, 2020Inventors: Hinrich Abken, Andreas Hombach
-
Patent number: 10808035Abstract: In a first aspect, the present disclosure relates to genetically modified T-cells having a chimeric antigen receptor for use in adoptive cell therapy for treating CD30+cancer in a subject need thereof. In particular, the present disclosure relates to a T-cell containing a specific chimeric antigen receptor being toxic to CD30+cancer cells while being non-toxic to CD30+non-cancer cells. In a further aspect, the present disclosure relates to a specific chimeric antigen receptor and the nucleic acid molecule encoding the receptor as well vectors and cells containing the same. Finally, the present disclosure relates to the use of the chimeric antigen receptor for use in improving persistence and amplification of lymphocyte containing the same and the use of specific peptides for improving persistence and amplification of genetically modified lymphocytes expressing the same.Type: GrantFiled: August 26, 2014Date of Patent: October 20, 2020Inventors: Markus Chmielewski, Andreas Hombach, Hinrich Abken
-
Patent number: 10023648Abstract: In a first aspect, the present invention relates to genetically modified T-cells having a chimeric antigen receptor (CAR) in a method for adoptive cell therapy for treating TOSO+ cancer, like B-cell leukemia/lymphoma, in a subject in need thereof. In particular, the present invention relates to a genetically engineered T-cell containing and expressing a specific chimeric antigen receptor being toxic to TOSO+ cancer cells while being less toxic or non-toxic to TOSO+ non-cancer cells, in particular, being non-toxic to normal B cells and its precursors. In a further aspect, the present invention relates to a specific chimeric antigen receptor and the nucleic acid molecule encoding the same as well as vectors and cells containing the same.Type: GrantFiled: May 27, 2016Date of Patent: July 17, 2018Inventors: Andreas Hombach, Elena Faitschuk, Hinrich Abken
-
Publication number: 20170145095Abstract: In a first aspect, the present invention relates to a recombinant polypeptide containing a domain comprising at least two antibody units whereby the first antibody unit is an anti-CD30 single chain antibody unit while the second antibody unit is a antibody unit being specific for an antigen present on the surface of a predetermined target cell. In particular, the present invention relates to a recombinant polypeptide containing at least the following domains starting from the N-terminus to the C-terminus: a first domain containing an anti-CD30 single chain antibody unit, in particular, HRS3 scFv of SEQ ID No. 2 or homologs thereof having at least 70% identity with SEQ ID No. 2 binding specifically to CD30, and an antibody unit said antibody unit being specific for an antigen present on the surface of a predetermined target cell, in particular, being specific for a tumor-associated antigen; optionally a spacer domain; a trans-membrane domain; and a cytoplasmatic signalling domain.Type: ApplicationFiled: July 16, 2015Publication date: May 25, 2017Inventors: Hinrich ABKEN, Andreas HOMBACH
-
Publication number: 20170037413Abstract: The present invention relates in a first aspect to a vector nucleic acid suitable for expressing at least one molecule of interest in a prokaryotic cell, in particular a bacterial cell, or on the surface of a prokaryotic cell or released by the prokaryotic cell. In particular, the present invention relates to a vector nucleic acid comprising a nucleic acid sequence encoding a Fim polypeptide. In addition, the present invention relates to a cell containing said vector as well as isolated recombinant protein containing at least a module being a Fim polypeptide and a module being a molecule of interest. In addition, the present invention relates to methods for the production of the molecule of interest using the vector nucleic acid according to the present invention. Finally, the present invention provides a kit of system containing said vector nucleic acid in particular for the production of recombinant molecule of interest.Type: ApplicationFiled: April 17, 2015Publication date: February 9, 2017Inventors: Markus CHMIELEWSKI, Hinrich ABKEN
-
Publication number: 20160347854Abstract: In a first aspect, the present invention relates to genetically modified T-cells having a chimeric antigen receptor (CAR) in a method for adoptive cell therapy for treating TOSO+ cancer, like B-cell leukemia/lymphoma, in a subject in need thereof. In particular, the present invention relates to a genetically engineered T-cell containing and expressing a specific chimeric antigen receptor being toxic to TOSO+ cancer cells while being less toxic or non-toxic to TOSO+ non-cancer cells, in particular, being non-toxic to normal B cells and its precursors. In a further aspect, the present invention relates to a specific chimeric antigen receptor and the nucleic acid molecule encoding the same as well as vectors and cells containing the same.Type: ApplicationFiled: May 27, 2016Publication date: December 1, 2016Inventors: Andreas HOMBACH, Elena FAITSCHUK, Hinrich ABKEN
-
Publication number: 20160200824Abstract: In a first aspect, the present disclosure relates to genetically modified T-cells having a chimeric antigen receptor for use in adoptive cell therapy for treating CD30+cancer in a subject need thereof. In particular, the present disclosure relates to a T-cell containing a specific chimeric antigen receptor being toxic to CD30+cancer cells while being non-toxic to CD30+non-cancer cells. In a further aspect, the present disclosure relates to a specific chimeric antigen receptor and the nucleic acid molecule encoding the receptor as well vectors and cells containing the same. Finally, the present disclosure relates to the use of the chimeric antigen receptor for use in improving persistence and amplification of lymphocyte containing the same and the use of specific peptides for improving persistence and amplification of genetically modified lymphocytes expressing the same.Type: ApplicationFiled: August 26, 2014Publication date: July 14, 2016Inventors: Markus Chmielewski, Andreas Hombach, Hinrich Abken
-
Publication number: 20050118185Abstract: Described are recombinant immunoreceptors composed of an extracellular antigen binding domain (scFv) and a transmembrane region derived from the CD3?-chain and/or the Fc?RI?-chain linked to an intracellular signaling domain with cell activation properties. Moreover, nucleic acid sequences encoding said immunoreceptor, immune cells expressing said immunoreceptor as well as therapeutic uses of said immunoreceptor, e.g. adoptive immunotherapy, are described.Type: ApplicationFiled: June 17, 2004Publication date: June 2, 2005Applicant: Cell Center Cologne GmbHInventors: Andreas Hombach, Hinrich Abken, Claudia Heuser